Serum Cystatin C as an Early Predictive Biomarker for Acute Kidney Injury (AKI) in Neonates: A PRISMA-DTA Systematic Review
Children · 05.09.2026 · 13 (9) · 1202
DOI: 10.3390/children13091202 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Children, online erschienen am 05.09.2026. Verfasst von Diana Cristina Potîrcǎ und 6 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Medicine, Faculty of Medicine, Lucian Blaga University of Sibiu, 550024 Sibiu, Romania. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Acute kidney injury (AKI) affects 12–40% of critically ill newborns and significantly increases mortality risk. Diagnosis currently relies on serum creatinine (sCr), which rises only after substantial renal damage, so early biomarkers are needed in this vulnerable population. Serum cystatin C (sCysC) is a candidate because it is produced at a constant rate by all nucleated cells.
Aim
The study aimed to investigate the diagnostic performance of sCysC for early detection of neonatal AKI.
Methods
This systematic review followed the PRISMA-DTA guidelines and is registered with PROSPERO (CRD420261302574). We searched four databases for studies measuring sCysC in neonates (0–28 days) with validated assays and creatinine-based AKI definitions as the reference standard. Studies were categorized by sampling timing as concurrent diagnostic or early predictive, and appraised with QUADAS-2 and QUIPS, respectively.
Results
Thirteen studies were included. In the early predictive group, sCysC was elevated at scheduled timepoints preceding creatinine-defined AKI, with AUC values of 0.670–1.000. The concurrent diagnostic studies reported sensitivities of 84.8–88.5%, specificities of 61.8–75.0%, and AUC values of 0.844–0.849. Reported cut-offs ranged from 0.60 to 2.87 mg/L, with one sepsis-associated AKI study reporting 9.4 mg/L. Conclusions: sCysC is a promising adjunctive biomarker whose earlier elevation may support earlier recognition of neonatal AKI. Standardized assays and validated population-specific thresholds are required before routine clinical use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctoral School of Medicine, Faculty of Medicine, Lucian Blaga University of Sibiu, 550024 Sibiu, Romania.
- Faculty of Medicine, Lucian Blaga University of Sibiu, 550024 Sibiu, Romania.
- Department of Neonatology, Clinical County Emergency Hospital, 550245 Sibiu, Romania.
- Department of Medical Sciences, Faculty of Medicine, Oradea University, 410087 Oradea, Romania.
- Department of Neonatology, Emergency County Hospital Bihor, 410167 Oradea, Romania.
- Department of Neonatology, Poznan University of Medical Sciences, 61-701 Poznan, Poland.
ORCID-Profile: Ioana Andrada Radu, Dumitru Alin Teacoe, Rareș Arseniu, Radu Galiș, Maria Livia Ognean
Zitieren
APA
Potîrcǎ, D. C., Radu, I. A., Teacoe, D. A., Arseniu, R., Galiș, R., Kramer, B. W., & Ognean, M. L. (2026). Serum Cystatin C as an Early Predictive Biomarker for Acute Kidney Injury (AKI) in Neonates: A PRISMA-DTA Systematic Review. Children, 13(9), 1202. https://doi.org/10.3390/children13091202
Vancouver
Potîrcǎ DC, Radu IA, Teacoe DA, Arseniu R, Galiș R, Kramer BW, et al. Serum Cystatin C as an Early Predictive Biomarker for Acute Kidney Injury (AKI) in Neonates: A PRISMA-DTA Systematic Review. Children. 2026;13(9):1202. doi:10.3390/children13091202
BibTeX
@article{Potrc2026,
author = {Potîrcǎ, Diana Cristina and Radu, Ioana Andrada and Teacoe, Dumitru Alin and Arseniu, Rareș and Galiș, Radu and Kramer, Boris W and Ognean, Maria Livia},
title = {Serum Cystatin C as an Early Predictive Biomarker for Acute Kidney Injury (AKI) in Neonates: A PRISMA-DTA Systematic Review},
journal = {Children},
year = {2026},
volume = {13},
number = {9},
pages = {1202},
doi = {10.3390/children13091202}
}
EUVIMED